Carlsmed, Inc. priced its initial public offering at $15.00 a share, offering 6,700,000 shares of common stock, to list on the Nasdaq Global Select Market under the symbol CARL. It filed a Form S-1 registration statement for an initial public offering on June 26, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, July 24, 2025).
Sell to companies like Carlsmed, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Carlsmed, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-06-26. It has amended it 1 time. It filed its final prospectus on 2025-07-24, at a public offering price of $15.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Carlsmed, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 30, 2026 | Leadership change: Leo Greenstein departs, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| September 8, 2026 | Leadership change: Jeffrey Bertolini appointed, Chief Operating Officer | — | Leadership changes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by B CAPITAL GROUP MANAGEMENT, L.P. | 27.8% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Casey M Tansey | 22% of the class | 5%+ stakes | Source |
| July 24, 2025 | Stake report, Schedule 13G, by Michael Cordonnier | 5.9% of the class | 5%+ stakes | Source |
Check before you invest in Carlsmed, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Carlsmed, Inc. and the records around it.
Carlsmed, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Nov 2025
- Who owns it
Companies that share a holder
- U.S. Venture Partners XII, L.P. also filed stake reports on 2 other companies: Mobia Medical, Inc. (Aug 2026), Shoulder Innovations, Inc. (Nov 2025)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q3 2025, newest first.
- MBX Biosciences, Inc. (Sep 2025)
- Gemini Space Station, Inc. (Sep 2025)
Watch Carlsmed, Inc.
Get an email when Carlsmed, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Carlsmed, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Carlsmed, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Carlsmed, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “CARL.”From the 424B4 filed 2025-07-24
Shares offered
This is an initial public offering of shares of common stock by Carlsmed, Inc. We are offering 6,700,000 shares of common stock, par value $0.00001 per share (“common stock”).From the 424B4 filed 2025-07-24
Offering price
The initial public offering price is $15.00 per share.From the 424B4 filed 2025-07-24
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to support the commercialization of the aprevo Technology Platform and expand and improve our product offerings, including approximately $24.7 million to support our increased sales and marketing efforts, approximately $45.9 million to fund our research and development activities to advance the aprevo Technology Platform, including the continued development of the aprevo Technology Platform for use in cervical spine fusion surgeries, and the remainder for working capital and general corporate purposes.From the 424B4 filed 2025-07-24
Revenue
For the years ended December 31, 2024 and 2023, we recognized revenue of $27.2 million and $13.8 million, respectively, representing year-over-year growth of 97.2%.From the S-1/A filed 2025-07-15
Net loss or income
For the year ended December 31, 2024, we recognized a gross margin of 73.8% and a net loss of $24.3 million, compared to a gross margin of 71.9% and a net loss of $18.9 million for the year ended December 31, 2023.From the S-1/A filed 2025-07-15
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-06-26 | Registration statement filed | S-1 |
| 2025-07-15 | Registration statement amended | S-1/A |
| 2025-07-24 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Carlsmed, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.